This article is more than 5 years old. Information may no longer be current.

LIPSIA-N-ACC

Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC Trial

Issue: June 2010

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Trial assessed the effects of N-acetylcysteine on contrast-induced nephropathy and reperfusion injury among patients with ST-segment elevation MI undergoing primary angioplasty with moderate contrast volumes.

Design: prospective, single blind, placebo-controlled, randomized
Patients: 251
Centers: single-center
Country: Germany

RESULTS: High-dose IV N-acetylcysteine (2 x 1,200 mg/day for 48 hours; n=126) did not provide additional clinical benefit compared with placebo (n=125) in respect to contrast-induced nephropathy and myocardial reperfusion injury among nonselected patients who underwent angioplasty with moderate doses of contrast medium and optimal hydration. Contrast-induced nephropathy occurred in 14% of patients in the N-acetylcysteine group vs. 20% in the placebo group (P=.28). Myocardial salvage indexes were similar for both treatment groups (43.5 vs. 51.5; P=.36).

Published in: J Am Coll Cardiol. 2010;55:2201-2209.

Click here to read more about the LIPSIA-N-ACC trial.